The South Korea Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market is gaining attention as advancements in rare hematologic malignancy research continue to accelerate. BPDCN, a rare and aggressive cancer of the blood and bone marrow, primarily arises from precursors of plasmacytoid dendritic cells and is often characterized by skin lesions, bone marrow involvement, and systemic...